Patients, pharmacy benefits managers and drugmakers alike are trying to figure out how to save money through further generics use and better prescription adherence.
The FDA says it won't need a clinical trial for approval of copycat versions, meaning the treatment for chronic dry eye could face cheaper rivals years earlier than previously expected.
Just a week after the top court said U.S. drugmakers can be sued over agreements that delay generics, the court has found that generic drugmakers cannot be sued in state courts when their products cause adverse reactions.
Ranbaxy Laboratories may be dealing with yet another FDA Form 483, this one for its plant in Mohali, and it may be interfering with it getting generic Diovan to market.
Ranbaxy Laboratories had the 6-month exclusive right to produce a generic of Novartis' blockbuster hypertension fighter Diovan. But the patent loss came and went months ago, and Ranbaxy's generic remains missing in action.
It's party time in Europe for generic drugmakers. The patent for Pfizer's erectile dysfunction drug Viagra falls off today and generics are expected to soon flood the market.
Two days ago the U.S. Supreme Court said pharma companies can be sued for pay-for-delay deals, and now the European Commission has fined Lundbeck and a cadre of companies €146 million ($195.5 million) for the same thing.
The good news from IMS Institute for Healthcare Informatics: Using prescription medicines properly could save $200 billion in annual U.S. healthcare costs. More good news, at least for the pharma business: The institute's ideas for saving money don't all translate to less spending on drugs, branded or otherwise.
The pay-for-delay ruling is in. That means legal experts and industry analysts are poring over the decision, trying to assess its consequences. Any consensus? By eschewing the Federal Trade Commission's position--that patent-settlement payments should be assumed anticompetitive--the Supreme Court left pharma some leeway. That's better than it might have been. But the choice also leaves a lot of uncertainty on the table. Here's a roundup of opinions and commentary >>
It is Pfizer that will get another chance to knock down an Alabama Supreme Court ruling on the safety of generic drugs, but it stands in for the entire drug development industry that wants to see the the ruling reversed.